Source-grounded facts extracted from Immix Biopharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Immix Biopharma, Inc. shareholders approved Ratification of Auditors at the 2026-05-22 meeting.
“The stockholders ratified the appointment of Crowe LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results of the voting for this proposal were as follows: For Against Abstentions Broker Non-Votes 42,276,496 11,526 18,442 —”
Immix Biopharma, Inc. shareholders approved Election of Directors at the 2026-05-22 meeting.
“The stockholders elected each of the individuals listed below to serve as a director of the Company until the next annual meeting of stockholders and until such director’s successor is duly elected and qualified. The results of the voting for this proposal were as follows: For Withheld Broker Non-Votes Ilya Rachman 35,738,887 121,893 6,445,684 Gabriel Morris 34,353,302 1,507,479 6,445,683 Jason Hsu 35,844,812 15,969 6,445,683 Magda Marquet 35,731,188 129,592 6,445,684 Helen C. Adams 35,677,258 183,522 6,445,684 Carey Ng 35,840,860 19,921 6,445,683 Jane Buchan 35,731,346 129,434 6,445,684 Yekaterina Chudnovsky 35,749,420 111,360 6,445,684 Nancy Chang 35,744,455 116,325 6,445,684”
Immix Biopharma, Inc. amended Amendment No. 1 to At The Market Offering Agreement with Citizens JMP Securities, LLC valued at aggregate offering price of up to $100,000,000 in an at the market offering (effective 2026-03-25).
“On March 25, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”) and Citizens JMP Securities, LLC entered into Amendment No. 1 (“Amendment No. 1”) to that certain At The Market Offering Agreement, dated June 3, 2025 (the “Sales Agreement”), pursuant to which the Company may offer and sell, from time to time, at its option, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), through Citizens JMP Securities, LLC, as sales agent (the “Sales Agent”), having an aggregate offering price of up to $100,000,000 (the “Shares”) in an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.